Filing Details

Accession Number:
0001209191-20-009880
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-18 07:25:07
Reporting Period:
2020-02-13
Accepted Time:
2020-02-18 07:25:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1721442 Mark Sabag C/O Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva L3 4951033
See "Remarks" Below No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2020-02-13 72,131 $13.03 0 No 4 S Direct
Ordinary Shares Acquisiton 2020-02-14 19,040 $0.00 19,040 No 4 M Direct
Ordinary Shares Acquisiton 2020-02-14 5,710 $0.00 24,750 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2020-02-14 5,710 $0.00 5,710 $0.00
Ordinary Shares Restricted Share Units Disposition 2020-02-14 19,040 $0.00 19,040 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,712 No 4 M Direct
0 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.8525 to $13.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  4. Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021.
  5. Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020.